Advancing Immunosuppressive Therapy in Solid Organ Transplantation: Integrating Pharmacogenomics, Therapeutic Drug Monitoring, and Precision Medicine

Learning objectives

Upon completion of this activity, participants should be able to:

• Explain the significance of pharmacogenomics and therapeutic drug monitoring (TDM) in optimizing immunosuppressive therapy for non-liver transplant recipients.
• Discuss common pharmacogenomic variants affecting key immunosuppressive drugs (e.g., tacrolimus, azathioprine).
• Apply a structured approach to patient care that integrates pharmacokinetics, pharmacodynamics, and pharmacogenomic data in the management of drug-drug, drug-gene, and drug-drug-gene interactions in transplant patients.

Intended audience

This webinar is appropriate for transplant medicine physicians, nurse practitioners, physician assistants, pharmacists, pathologists, as well as laboratory directors, lab supervisors, and laboratory send-out coordinators/managers.

Credit

The following types of credit are offered for this event:

ASCLS P.A.C.E.^®

Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of 1.0 P.A.C.E.® contact hour.

State of Florida

Mayo Clinic Laboratories is approved as a Continuing Education Accrediting Agency for the Clinical Laboratory Sciences for the State of Florida. Florida Board of Clinical Laboratory Personnel has designated this program for General credit. This program has been approved for 1.0 contact hour.